Better Health for All

The company's core product, neffy, is an FDA-approved, needle-free epinephrine nasal spray for emergency treatment of severe allergic reactions, representing the first new delivery method in over 35 years.

This product is designed to improve patient outcomes by addressing fear of needles and increasing portability, leading to earlier treatment. The company's entire portfolio is dedicated to this beneficial product. However, neffy has numerous safety warnings, including potential for arrhythmias, fatal ventricular fibrillation, and exacerbation of underlying conditions, with common side effects such as nasal discomfort and headache. While the company provides comprehensive safety information and reporting mechanisms, specific adverse event rates per million users are not provided. The company offers a co-pay savings program limiting costs to $25 for most commercially insured patients and a cash price of $199 for two doses. A Patient Assistance Program provides neffy at no cost for eligible uninsured or underinsured U.S. residents. The neffyinSchools program has distributed neffy to over 6,600 schools in more than 20 states, and the product is approved for children as young as 4 years old, expanding access to younger, school-aged children who make up nearly 23% of those needing epinephrine. The company is actively developing neffy 1mg for children weighing 15 to 30 kg. The company provides education through programs like neffyConnect and webinars for school nurses and administrators.

Fair Money & Economic Opportunity

SPRY.US is a biopharmaceutical company focused on developing and commercializing products for severe allergic reactions.

The company does not offer lending or deposit services to consumers, provide consumer credit products, manage customer finance data, or operate as a financial institution. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, financial literacy initiatives, debt burden ratio, and geographic inclusion of financial access points, are not applicable to its core business model. The company's product, neffy, is described as having a "no needle, no injection" approach and compact size, which relates to ease of use for a medical device, not the simplicity of financial products.

Fair Pay & Worker Respect

No specific, concrete data points were found in the provided articles for any of the KPIs related to Fair Pay & Worker Respect.

The articles primarily discuss company products, regulatory events, and SEC filing availability without detailing employee compensation, safety, engagement, or contract terms.

Honest & Fair Business

ARS Pharmaceuticals has a comprehensive whistleblower policy, including a 24/7 confidential, toll-free hotline and a Compliance Web Form, both operated by an independent third party.

The company prohibits retaliation against employees for reporting and states it employs an objective and thorough investigation process. It also explicitly allows individuals to communicate with governmental entities under whistleblower protections. However, the policy does not specify training frequency, uptake rates, or resolution times for reports. A member of the Company’s Board of Directors is a General Partner at OrbiMed Advisors LLC, which entered into an agreement to purchase rights and royalty interests on net product sales of neffy, indicating a potential conflict of interest. The company has an anti-corruption policy that prohibits offering items of value to healthcare professionals to influence prescribing habits and states that its Renaissance Agreement can be terminated for violations of anti-corruption laws. Its Code of Business Conduct and Ethics also addresses the Foreign Corrupt Practices Act, but there is no evidence of risk-based training or third-party monitoring.

Kind to Animals

SPRY.US's research and development activities involve the use of various animal models, including mice, rats, canines, minipigs, and non-human primates.

The company operates under the FDA Animal Rule, which permits drug approval based on animal studies when human efficacy studies are unethical or infeasible. This policy allows for discretionary testing, with legal mandates overriding alternatives. The FDA has approved 16 products through the Animal Rule, indicating a reliance on animal testing for product development. The company's engagement in animal-free R&D collaboration is limited to mentioning emerging technologies as complementary tools, with no evidence of formal participation or contribution to multi-stakeholder initiatives. There is no public position on animal welfare legislation, and the company is silent on industry standards, despite political headwinds from anti-laboratory animal activists.

No War, No Weapons

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing products for severe allergic reactions.

Its core business does not involve defense or arms-related activities, and there is no evidence of revenue derived from arms or defense contracts. The company has no exposure to any weapons, controversial or otherwise, as its operations are entirely within the pharmaceutical sector. There is no evidence of dual-use technology development, sales to embargoed regimes, or involvement in intelligence or surveillance activities. While the company has a corporate sponsorship agreement with Food Allergy Research and Education, Inc., this is not classified as a peacebuilding or disarmament initiative. No information is available regarding lobbying on arms control, procurement from conflict zones, or specific ethical red lines related to weapons.

Planet-Friendly Business

ARS Pharmaceuticals, Inc. states that its facilities and operations are in material compliance with all applicable Environmental Laws, and there are no conditions that could lead to liability exceeding a defined Threshold Amount.

The company has not received any notice of environmental violations or non-compliance that could exceed this Threshold Amount, nor is it aware of any such threats. No judicial proceedings or governmental actions are pending or threatened under Environmental Law, and there have been no releases of Hazardous Materials in violation of Environmental Laws or in amounts that could exceed the Threshold Amount.

Respect for Cultures & Communities

The company has established 8 formal partnerships with organizations such as the Asthma and Allergy Foundation of America, National Association of School Nurses, School Health Corp., Food Allergy Research & Education, Allergy & Asthma Network, Allergy, Asthma & Immunology Research, Food Allergy and Anaphylaxis Connection Team, and Snack Safely.

For community concerns, specifically regarding product side effects, the company provides a dedicated phone number (1-877-MY-NEFFY) and an email address (CommunityPrograms@ars-pharma.com) for reporting. Additionally, the company hosted a webinar for school nurses and administrators on January 22, 2025, regarding its neffyInSchools program.

Safe & Smart Tech

The company's Audit Committee reviews material risks related to data privacy, technology, and information security, including cybersecurity threats and internal controls.

It has an incident response policy and a Cybersecurity Incident Management Team. The company implements encryption for certain data, uses authentication technology for some systems, and conducts penetration testing. Vulnerability management processes are in place, and employee training is conducted. The company maintains cybersecurity insurance and uses third-party service providers for risk management. It publishes privacy policies, effective June 14, 2024, and states it takes steps to detect, mitigate, and remediate vulnerabilities. The company collects various types of personal data, including contact, demographic, and online activity data, and uses it for service delivery, research, marketing, and compliance. It shares data with affiliates, service providers, and advertising partners. Users can opt-out of marketing emails and manage cookies, but the service does not respond to “Do Not Track” signals. Data is retained as long as needed or for legal obligations. The company acknowledges inherent security risks and states it cannot guarantee security. It is subject to and mentions compliance with HIPAA, HITECH, GDPR (EU and UK), Australia’s Privacy Act, and China’s PIPL, and provides EU users with GDPR-related rights. The company has experienced successful phishing attempts that did not have a material adverse effect and vendor email account hacks.